In diffuse large B-cell lymphoma (DLBCL) cell lines, inhibitors of mTOR [21], PI3K, Bcl-2, and chemotherapeutic agents were reported to show synergistic activity when combined with ibrutinib [22]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.